We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioMarin's (BMRN) Gene Therapy Enters First Phase III Study
Read MoreHide Full Article
BioMarin Pharmaceutical Inc. (BMRN - Free Report) announced initiation of the first phase III study, evaluating the 6e13 vg/kg dose of its investigational gene therapy, valoctocogene roxaparvovec, for treatment of patients with severe hemophilia A. The company plans to enroll the first patient in the second phase III study with the 4e13 vg/kg dose at the beginning of 2018 for the given indication.
The two phase III studies, GENEr8-1 and GENEr8-2, were designed to evaluate the efficacy and safety of valoctocogene roxaparvovec in patients with severe hemophilia A across the two doses mentioned above. While the primary endpoint in both the studies will be factor VIII (a blood clotting protein) activity level achieved following administration of valoctocogene roxaparvovec, the secondary endpoints will measure annualized factor VIII replacement therapy use rate and annualized bleed rate.
BioMarin’s share price has gained 9.7% in the last 12 months, comparing favorably with the industry’s increase of 2.6%.
We remind investors that earlier this month, BioMarin presented an updated data from a phase I/II study on valoctocogene roxaparvovec at the American Society of Hemophilia. The findings suggested that a one-time infusion of valoctocogene roxaparvovec has potential to eliminate non-stop bleeding for patients suffering severe hemophilia A with a very acceptable safety profile.
The company is also planning to start another phase I/II trial to evaluate valoctocogene roxaparvovec with the 6e13kg/vg dose on approximately 10 patients, who are adeno-associated virus type 5 (AAV5) positive, in the first half of 2018.
Notably, last March, BioMarin had announced that the FDA granted an Orphan Drug designation to valoctocogene roxaparvovec for treatment of patients with hemophilia A.
Additionally, in February, valoctocogene roxaparvovec has been granted an access to Priority Medicines, a regulatory initiative by the European Medicines Agency. This proposal offers an early and enhanced support to optimize regulatory applications. This would help patients get fast benefits from the therapies that promise to improve their quality of life.
It is important to note that the current marketed therapies for hemophilia include Bayer AG’s (BAYRY - Free Report) Kovaltry, approved in both the United States and the EU in early 2016 both for children and the adults.
Another company, Alnylam Pharmaceuticals (ALNY - Free Report) , is developing its hemophilia candidate, fitusiran, in partnership with Sanofi (SNY - Free Report) . Several mid to late stage studies are also underway on the candidate.
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
BioMarin's (BMRN) Gene Therapy Enters First Phase III Study
BioMarin Pharmaceutical Inc. (BMRN - Free Report) announced initiation of the first phase III study, evaluating the 6e13 vg/kg dose of its investigational gene therapy, valoctocogene roxaparvovec, for treatment of patients with severe hemophilia A. The company plans to enroll the first patient in the second phase III study with the 4e13 vg/kg dose at the beginning of 2018 for the given indication.
The two phase III studies, GENEr8-1 and GENEr8-2, were designed to evaluate the efficacy and safety of valoctocogene roxaparvovec in patients with severe hemophilia A across the two doses mentioned above. While the primary endpoint in both the studies will be factor VIII (a blood clotting protein) activity level achieved following administration of valoctocogene roxaparvovec, the secondary endpoints will measure annualized factor VIII replacement therapy use rate and annualized bleed rate.
BioMarin’s share price has gained 9.7% in the last 12 months, comparing favorably with the industry’s increase of 2.6%.
We remind investors that earlier this month, BioMarin presented an updated data from a phase I/II study on valoctocogene roxaparvovec at the American Society of Hemophilia. The findings suggested that a one-time infusion of valoctocogene roxaparvovec has potential to eliminate non-stop bleeding for patients suffering severe hemophilia A with a very acceptable safety profile.
The company is also planning to start another phase I/II trial to evaluate valoctocogene roxaparvovec with the 6e13kg/vg dose on approximately 10 patients, who are adeno-associated virus type 5 (AAV5) positive, in the first half of 2018.
Notably, last March, BioMarin had announced that the FDA granted an Orphan Drug designation to valoctocogene roxaparvovec for treatment of patients with hemophilia A.
Additionally, in February, valoctocogene roxaparvovec has been granted an access to Priority Medicines, a regulatory initiative by the European Medicines Agency. This proposal offers an early and enhanced support to optimize regulatory applications. This would help patients get fast benefits from the therapies that promise to improve their quality of life.
It is important to note that the current marketed therapies for hemophilia include Bayer AG’s (BAYRY - Free Report) Kovaltry, approved in both the United States and the EU in early 2016 both for children and the adults.
Another company, Alnylam Pharmaceuticals (ALNY - Free Report) , is developing its hemophilia candidate, fitusiran, in partnership with Sanofi (SNY - Free Report) . Several mid to late stage studies are also underway on the candidate.
BioMarin Pharmaceutical Inc. Price
BioMarin Pharmaceutical Inc. Price | BioMarin Pharmaceutical Inc. Quote
Zacks Rank
Biomarin carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>